Kintor Pharmaceutical Limited
KNTPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.21 | -0.47 | -0.00 |
| FCF Yield | -39.91% | -74.47% | -0.03% | -4.53% |
| EV / EBITDA | -3.81 | -0.31 | -3.67 | -0.22 |
| Quality | ||||
| ROIC | -31.33% | -18.92% | -51.38% | 403.18% |
| Gross Margin | -94.60% | 0.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 1.28 | 0.36 | 1.01 | 2.04 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | – | – |
| Free Cash Flow Growth | 48.56% | -39,375.29% | 12.32% | -150.63% |
| Safety | ||||
| Net Debt / EBITDA | 0.11 | 0.18 | -0.30 | -0.19 |
| Interest Coverage | -15.58 | -15.73 | -115.37 | -336.65 |
| Efficiency | ||||
| Inventory Turnover | 4.39 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,237.49 | -590.24 | 70,013.37 | 11,240.38 |